<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>Roche Bid Backed</title>
    <meta content="20" name="publication_day_of_month"/>
    <meta content="12" name="publication_month"/>
    <meta content="1990" name="publication_year"/>
    <meta content="Thursday" name="publication_day_of_week"/>
    <meta content="Financial Desk" name="dsk"/>
    <meta content="5" name="print_page_number"/>
    <meta content="D" name="print_section"/>
    <meta content="3" name="print_column"/>
    <meta content="Business" name="online_sections"/>
    <docdata>
      <doc-id id-string="409706"/>
      <doc.copyright holder="The New York Times" year="1990"/>
      <series series.name="COMPANY NEWS"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">MERGERS, ACQUISITIONS AND DIVESTITURES</classifier>
        <org class="indexing_service">GENENTECH INC</org>
        <org class="indexing_service">FEDERAL TRADE COMMISSION (FTC)</org>
        <org class="indexing_service">ROCHE HOLDING LTD</org>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business</classifier>
        <classifier class="online_producer" type="general_descriptor">Mergers, Acquisitions and Divestitures</classifier>
        <classifier class="online_producer" type="general_descriptor">Finances</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="19901220T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9C0CE1D81539F933A15751C1A966958260" item-length="74" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>Roche Bid Backed</hl1>
      </hedline>
      <byline class="print_byline">AP</byline>
      <dateline>WASHINGTON, Dec. 19</dateline>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>The Federal Trade Commission approved the acquisition of Genentech Inc., an American biotechnology concern, by Roche Holding Ltd., the Swiss pharmaceutical company, but required Roche to issue United States licenses for its patented AIDS treatment. It told Roche that for 10 years it must grant the licenses for its CD-4-based therapeutics because the Genentech acquisition might lessen competition in the United States for such therapeutics.</p>
      </block>
      <block class="full_text">
        <p>The Federal Trade Commission approved the acquisition of Genentech Inc., an American biotechnology concern, by Roche Holding Ltd., the Swiss pharmaceutical company, but required Roche to issue United States licenses for its patented AIDS treatment. It told Roche that for 10 years it must grant the licenses for its CD-4-based therapeutics because the Genentech acquisition might lessen competition in the United States for such therapeutics.</p>
        <p>COMPANY NEWS</p>
      </block>
    </body.content>
  </body>
</nitf>
